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To Rb or not to Rb
 
aution and more experiments are in order, say Jiang and 
Zacksenhaus (page 185), for drug companies hoping
to activate the Rb pathway with anticancer compounds. 
The authors have found that expression of a constitutively 
active version of the tumor suppressor Rb can result in the 
counterintuitive outcome of more tumor formation.
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Initially, expression of 
activated Rb in transgenic 
mice does suppress cell 
proliferation somewhat. 
But Jiang and Zacksenhaus 
suggest that this growth 
suppression may also 
positively select for cells 
with transforming 
mutations. Usually most 
cells with such mutations 
Active Rb causes nodule formation.
 
would be eliminated by apoptosis. But Rb is known to 
suppress apoptosis, and this appears to occur in the 
 
Squeezing for healing
 
chicken chemokine can help heal wounds by inducing 
fibroblasts to become myofibroblasts, according to results 
reported by Feugate et al. on page 161. The contractile 
myofibroblasts help close the wound by pulling together the 
necessary cells and matrix.
Chemokines are better known for their activities in the immune 
system, but increased production of chicken chemotactic and 
angiogenic factor (cCAF) has also been observed during wound 
healing. Now Feugate et al. report that cCAF reduces fibroblast 
proliferation by 25%, not by increasing cell death, but by inducing 
differentiation of fibroblasts into myofibroblasts. The differ-
entiated cells make 
 
 
 
-smooth muscle actin (
 
 
 
-SMA), and 
have an increased ability to contract a collagen gel.
Regular application of cCAF to a chicken wound accelerates 
the early stages of wound healing by almost two days. The 
authors suggest that a peptide mimetic might accelerate wound 
healing in humans, whereas a cCAF antagonist might reduce 
the scar-inducing numbers of myofibroblasts in conditions 
such as scleroderma. 
 
 
Wounds treated with cCAF (right) heal faster.
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Polo meets the APC
 
olo kinases have been linked to activation of the 
anaphase promoting complex (APC) during mitosis, 
but the importance of this effect has been debated. 
Now, May et al. study this problem using polo-like kinase 
Plo1 from fission yeast (page 23). They show that Plo1-
mediated activation is essential—a metaphase 
arrest results when Plo1 can no longer bind avidly to 
the Cdc23 subunit of the APC.
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The authors came to 
this conclusion after 
identifying mutants 
that were dependent 
on high Plo1 expression 
for their survival. One 
of the mutants made 
a Cdc23 protein that 
interacted poorly with 
Plo1, a deficit that 
May et al. suggest is 
overcome by excess 
Plo1. Following up on 
Mitotic arrest results when APC 
and Plo1 cannot interact.
 
this clue, May et al. mapped the Plo1–Cdc23 interaction 
to the noncatalytic domain of Plo1 and the TPR domain 
of Cdc23.
The APC subunit or residues that act as the Plo1 
target remain unknown. In tracking down this target, 
May et al. plan to continue their analysis of the APC 
at the level of individual subunits or residues rather 
than as a whole complex. 
 
 
 
transgenic mice. In mammary tissue, where the tumors are 
eventually seen, apoptosis during involution is reduced by 
44%.
This failure in apoptosis may give rise to the focal 
hyperplastic nodules that the authors see in approximately 
one third of the transgenic animals. The large tumors that 
finally arise are fewer in number than these nodules, and no 
longer express the activated Rb transgene, suggesting that 
extinction of Rb expression may be at least one of the steps 
leading to final transformation.
Mammary tissue may be particularly susceptible to such 
a tumor-formation pathway because a large proportion of 
the epithelium turns over during each estrous cycle, as 
the tissue is prepared for a potential pregnancy and then 
restored to its former state. Similar problems may arise in 
human tissues that remodel extensively, such as breast, 
ovary, and endometrium. Zacksenhaus suggests, therefore, 
that antiproliferative drugs should be paired with proapoptotic 
drugs in new combinatorial drug trials. 
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